Evaluation of Ecallantide for Treatment of Angiotensin Converting Enzyme (ACE) Inhibitor Induced Angioedema

Inclusion Criteria:

- Males and females 18 years of age or older

- Must currently be on ACE inhibitor therapy and have received a dose within 36 hours

- Presenting with ACEIA of the head/neck region within 12 hours after onset

- All females must have a negative urine pregnancy test prior to administration of the
study drug. Those who have had a total hysterectomy, bilateral oophorectomy or are two
years post-menopausal do not require a pregnancy test.

Exclusion Criteria:

- Hypersensitivity to ecallantide

- Pregnancy or breast feeding

- Patients who have had angioedema and were not concurrently on an ACE inhibitor

- Patients exhibiting urticaria

- Patients who are intubated or who have a tracheostomy related to the current episode
of angioedema

- Opinion of the investigator that the patient would not be a good candidate

- Participation in another investigational study within 30 days prior to enrollment